#ScienceLink #Madrid2026 #ESMO26 #HBI8000303 #HBI8000 #Nivolumab
在 HBI-8000-303（III 期；n=404）中，HBI-8000（口服 HDAC 抑制剂）联合 nivolumab 相比安慰剂联合 nivolumab，改善了非葡萄膜黑色素瘤不可切除或转移性且既往未接受过抗 PD-(L)1 治疗患者的 SLP。
⏰ 中位随访：37 个月
⏳ SLP：11.7 对 7.4 个月（HR 0.73；96% CI：0.56–0.95；p=0.0141）
🎯 TRO：41.4% 对 32.3%（p=0.0569；差异无统计学意义）
📊 SG 仍不成熟
⚠️ 与治疗相关的 3–4 级不良事件：54.8% 对 17.9%。因相关不良事件永久停药：14.1% 对 5.0%。
🔗 阅读/收听完整新闻：https://buff.ly/e2X5xs8
69 浏览 · 0 赞 · 0 转发 · 0 回复
Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity
https://esmocongress.esmo.orgResults from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)
https://esmocongress.esmo.orgFinal pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)
https://esmocongress.esmo.orgPrimary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma
https://esmocongress.esmo.org- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)
https://esmocongress.esmo.org来源：ScienceLink · x.com